http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
백혈병 미세잔존질환 정량검출을 위한 실시간 역전사중합효소연쇄반응법의 유용성
조정애 ( Jeung Ai Cho ),김다운 ( Da Woon Kim ),정성두 ( Seong Du Jeong ),천지선 ( Ji Seon Cheon ),나경아 ( Gyeong Ah Na ),김혜란 ( Hye Ran Kim ),김진각 ( Jin Gak Kim ),김인환 ( In Hwan Kim ),김수현 ( Soo Hyun Kim ),신명근 ( Myung 대한임상검사과학회 2009 대한임상검사과학회지(KJCLS) Vol.41 No.1
Chromosomal rearrangements are major pathology in hematological malignancies. The detection of minimal residual disease (MRD) for these gene rearrangements helps in monitoring treatment outcomes and predicting prognosis of patients. Recently, quantification of these gene transcripts based on real-timequantitative polymerase chain reaction (RQ-PCR) has been used as MRD detection. The purpose of this study is to ensure the usefulness of the RQ-PCR technique for detecting MRD in hamatological malignancy patients. The patients had been diagnosed to AML1-ETO positive AML, PML-RARa positive AML and BCR-ABL positive MPN at Chonnam National University Hwasun Hospital from Jan. 2006 to Aug. 2008. The fusion transcript was quntified by RQ-PCR and analyzed in comparison to conventional cytogenetics, FISH and RT-PCR. The fusion gene transcript was quantified by RQ-PCR in 57 samples from 14 patients with AML1-ETO positive AML, 79 samples from 27 patients with PML-RARa positive AML and 108 samples from 36 patients with CML. At diagnosis, the quantitative fusion transcripts for AM1-ETO, PML-RARa and BCR-ABL showed the range of 0.485552651~10.82233683 (mean 3.782217131, SD 2.998052348), 0.005300395~0.29267494 (mean 0.056901315, SD 0.080131381) and 0.1293929~12.94826849 (mean 1.701935665, SD 2.200913158). The increase of AML1-ETO fusion gene transcripts preceded morphologic relapse in two patients. Quantification of fusion gene transcripts by RQ-PCR could detected MRD in samples which were negative by in cytogenetic analysis or FISH. Our findings indicated that quantitative analysis of AML1-ETO, PML-RARa and BCR-ABL transcripts by RQ-PCR might be a useful tool for the monitoring of minimal residual disease in hematological malignancies.
논문 1 : 백혈병 미세잔존질환 정량검출을 위한 실시간 역전사중합효소연쇄반응법의 유용성
조정애 ( Jeung Ai Cho ),김다운 ( Da Woon Kim ),정성두 ( Seong Du Jeong ),천지선 ( Ji Seon Cheon ),나경아 ( Gyeong Ah Na ),김진각 ( Jin Gak Kim ),김인환 ( In Hwan Kim ),김수현 ( Soo Hyun Kim ),신명근 ( Myung Geun Shin ) 대한임상병리사협회 2008 임상혈액검사학회 발표자료집 Vol.10 No.1
Background : Chromosomal rearrangements are major pathology inhematological malignancy. The detection of minimal residual disease(MRD) for these gene rearrangements helps in monitoring treatment outcomes and predicting prognosis. patients. Recently, quantification of these gene transcripts based on real-time quantitative polymerase chain reaction (RQ-PCR) has been used as MRD detection. The purpose of this study is to ensure the usefulness of the RQ-PCR technique for detecting MRD in hematological malignancy patients. Methods : The patients had been diagnosed to AML1-ETO positive AML, PML-RARa positive AML and BCR-ABL positive MPN (CML) at Chonnam National University Hwasun Hospital (CNUHH, Hwasun, Korea) from Jan. 2006 to Aug. 2008. The fusion transcript was quantified by RQ-PCR and analyzed in comparison to conventional cytogenetics, FISH and RT-PCR. Results : The fusion gene transcript was quantified by RQ-PCR in 57 samples from 14 patients with AML1-ETO positive AML, 79 samples from 27 patients with PML-RARa positive AML and 108 samples from 36 patients with CML. At diagnosis, the quantitative fusion transcripts for AM1-ETO, PML-RARa and BCR-ABL showed the range of 0.485552651 ~ 10.82233683 (mean 3.782217131, SD 2.998052348), 0.005300395 ~ 0.29267494 (mean 0.056901315, SD 0.080131381) and 0.1293929 ~ 12.94826849 (mean 1.701935665, SD 2.200913158). The increase of AML1-ETO fusion gene transcripts preceded morphologic relapse in two patients. Quantification of fusion gene transcripts by RQ-PCR could detected MRD in samples which were negative by in cytogenetics analysis or FISH. Conclusions : Our findings indicated that quantitative analysis of AML1-ETO, PML-RARa and BCR-ABL transcripts by RQ-PCR might be a useful tool for the monitoring of minimal residual disease in hematological malignancy.